Company intelligence / Profile preview

Qingfeng Pharmaceutical Group

Ganzhou/Zhanggong District, Jiangxi Province, Chinaqfyy.com.cn ↗

Ownership: Private
Development stage: Other

Overview

Jiangxi Qingfeng Pharmaceuticals has a diversified clinical pipeline including approved small molecule drugs for anesthesia and herbal medicines for dyspepsia and dysentery. Their lead candidates include a rabies vaccine and an influenza therapeutic (GP681) in Phase 3 and NDA filed stages, respectively, alongside other herbal medicines in late-stage development.

Therapeutic areas: NeurologyInfectious DiseasesDermatologyGastroenterologyEndocrinologyOncologyImmunology
Modalities: Small moleculeHerbal medicineProphylactic vaccineRadiopharmaceuticals and diagnostic agent
Industry: Biotech

Partnerships

GinkgoPharma (co-development of GP681)Shanghai Gopherwood Biotech Co., Ltd. (BR790 trial sponsor)

Beyond the preview

Go deeper on Qingfeng Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingfeng Pharmaceutical Group.

Explore the full profile